Showing results (121-130 of 143) with videos related to

Sort By:
Pageof 15
The British Journal of Dermatology|January 4, 2007
CD30+ large cell transformation of mycosis fungoides after psoralen plus ultraviolet A photochemotherapyJ Ogino, K Saga, M Kagaya, et al.
The Journal of Investigative Dermatology|December 1, 1983
Combined chemical and electron microscopic studies of pheomelanosomes in human red hairK Jimbow, O Ishida, S Ito, et al.
Experimental Cell Research|December 1, 1993
Identification of a cDNA coding for a Ca(2+)-binding phosphoprotein (p90), calnexin, on melanosomes in normal and malignant human melanocytesJ Dakour, T Vinayagamoorthy, K Jimbow, et al.
Cancer Research|March 1, 1984
Characterization of melanogenesis and morphogenesis of melanosomes by physicochemical properties of melanin and melanosomes in malignant melanomaK Jimbow, Y Miyake, K Homma, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1995
Photodynamic action of ultraviolet A: induction of cellular hydroperoxidesS Schmitz, C Garbe, K Jimbow, et al.
The Journal of Investigative Dermatology|December 14, 1999
Selective incorporation and specific cytocidal effect as the cellular basis for the antimelanoma action of sulphur containing tyrosine analogsP D Thomas, H Kishi, H Cao, et al.
The Journal of Investigative Dermatology|October 26, 2001
Induction of apoptosis in melanoma cell lines by p53 and its related proteinsT Yamashita, T Tokino, H Tonoki, et al.
Biochemical Pharmacology|August 26, 1998
Synthesis and antitumour effect of the melanogenesis-based antimelanoma agent N-propionyl-4-S-cysteaminylphenolM Tandon, P D Thomas, M Shokravi, et al.
Pigment Cell Research|August 22, 2000
Assembly, target-signaling and intracellular transport of tyrosinase gene family proteins in the initial stage of melanosome biogenesisK Jimbow, J S Park, F Kato, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 1, 1984
[Malignant melanoma in Japan: unique distribution and effect of DAV chemoimmunotherapy (part II)]K Ishihara, K Hayasaka, S Ikeda, et al.
Pageof 15